Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Borg

Showing results (101-110 of 224) with videos related to

Pageof 23
Sort By:
Cancer Medicine|October 12, 2016
Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinomaFrédéric Fiteni, Sophie Paget-Bailly, Mathieu Messager, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 22, 2014
In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cellsCéline Leboeuf, Laurent Mailly, Tao Wu, et al.
International Journal of Cancer|December 3, 2014
CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopesCharline Vauchy, Clementine Gamonet, Christophe Ferrand, et al.
Oncoimmunology|April 11, 2018
SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contextsMarie Kroemer, Laurie Spehner, Patricia Mercier-Letondal, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 20, 2024
Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancerRomain Chautard, Morgane Caulet, Olivier Bouché, et al.
Clinical Colorectal Cancer|August 2, 2011
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR studyJaafar Bennouna, Christophe Borg, Jean-Pierre Delord, et al.
Oncotarget|September 17, 2017
GABARAPL1 tumor suppressive function is independent of its conjugation to autophagosomes in MCF-7 breast cancer cellsLaura Poillet-Perez, Marine Jacquet, Eric Hervouet, et al.
Molecular Oncology|January 1, 2023
SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic featuresAngélique Vienot, Franck Monnien, Caroline Truntzer, et al.
The Oncologist|June 21, 2025
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO studyJean-Frédéric Blanc, Mohamed Bouattour, Ludovic Gauthier, et al.
Plos One|July 13, 2011
Neuropilin-2 expression promotes TGF-β1-mediated epithelial to mesenchymal transition in colorectal cancer cellsCamille Grandclement, Jean René Pallandre, Séverine Valmary Degano, et al.
Pageof 23

Showing results (101-110 of 224) with videos related to

Sort By:
Pageof 23
Cancer Medicine|October 12, 2016
Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinomaFrédéric Fiteni, Sophie Paget-Bailly, Mathieu Messager, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 22, 2014
In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cellsCéline Leboeuf, Laurent Mailly, Tao Wu, et al.
International Journal of Cancer|December 3, 2014
CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopesCharline Vauchy, Clementine Gamonet, Christophe Ferrand, et al.
Oncoimmunology|April 11, 2018
SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contextsMarie Kroemer, Laurie Spehner, Patricia Mercier-Letondal, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 20, 2024
Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancerRomain Chautard, Morgane Caulet, Olivier Bouché, et al.
Clinical Colorectal Cancer|August 2, 2011
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR studyJaafar Bennouna, Christophe Borg, Jean-Pierre Delord, et al.
Oncotarget|September 17, 2017
GABARAPL1 tumor suppressive function is independent of its conjugation to autophagosomes in MCF-7 breast cancer cellsLaura Poillet-Perez, Marine Jacquet, Eric Hervouet, et al.
Molecular Oncology|January 1, 2023
SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic featuresAngélique Vienot, Franck Monnien, Caroline Truntzer, et al.
The Oncologist|June 21, 2025
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO studyJean-Frédéric Blanc, Mohamed Bouattour, Ludovic Gauthier, et al.
Plos One|July 13, 2011
Neuropilin-2 expression promotes TGF-β1-mediated epithelial to mesenchymal transition in colorectal cancer cellsCamille Grandclement, Jean René Pallandre, Séverine Valmary Degano, et al.
Pageof 23